DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development and commercialization of novel vaccines and immuno-oncology therapeutics. The firm focuses on leveraging the body's innate and adaptive immune responses through toll-like receptor stimulation. It offers products for vaccines, cancer immunotherapy, and immune-mediated diseases. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Berkeley, CA.
Company profile
Ticker
DVAX
Exchange
Website
CEO
Ryan Spencer
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
SEC CIK
Corporate docs
IRS number
330728374
DVAX stock data
()
Investment data
Securities sold
Number of investors
Calendar
5 Nov 20
24 Nov 20
31 Dec 20
News
Financial summary
| Quarter (USD) | Sep 20 | Jun 20 | Mar 20 | Sep 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 19 | Dec 18 | Dec 17 | Dec 16 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Financial data from company earnings reports.
Recent insider trades
| Date | Owner | Security | Transaction | Code | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|
| 23 Sep 20 | Peter R. Paradiso | Stock Option Common Stock | Grant | Aquire A | No | 4.53 | 50,000 | 226.5K | 50,000 |
| 17 Jul 20 | Janssen Robert | Common Stock | Sell | Dispose S | Yes | 11.09 | 50,000 | 554.5K | 127,266 |
| 17 Jul 20 | Eastland Julia Marie | Stock Option Common Stock | Grant | Aquire A | No | 11.37 | 50,000 | 568.5K | 50,000 |
Institutional ownership Q3 2020
80.0% owned by funds/institutions
13F holders |
Current |
|---|---|
| Total holders | 166 |
| Opened positions | 41 |
| Closed positions | 28 |
| Increased positions | 50 |
| Reduced positions | 40 |
13F shares |
Current |
|---|---|
| Total value | 877.07M |
| Total shares | 88.16M |
| Total puts | 842.2K |
| Total calls | 797.4K |
| Total put/call ratio | 1.1 |
Largest owners |
Shares | Value |
|---|---|---|
| STT State Street | 11.6M | $50.13M |
| FHI Federated Hermes | 10.95M | $47.29M |
| Bain Capital Life Sciences Investors | 10.9M | $47.07M |
| BLK BlackRock | 8.16M | $35.27M |
| Vanguard | 5.21M | $22.5M |
| Chicago Capital | 3.93M | $16.98M |
| Partner Fund Management | 2.94M | $12.69M |
| Redmile | 2.55M | $11.01M |
| AMP Ameriprise Financial | 2.11M | $9.08M |
| Citadel Advisors | 2.1M | $9.06M |
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. junior Avg
|
|
New words:
BMGF, book, broader, compliant, compound, deferred, Foundation, fourth, GASC, invoice, Melinda, objective, October, outpace, output, promptly, publicly, recoverable, reliant, replenished, scale, Scotland, seasonal, twelve, Valneva
Removed:
paragraph, preceding
Financial reports
10-Q
2020 Q3
Quarterly report
5 Nov 20
10-Q
2020 Q2
Quarterly report
6 Aug 20
10-Q
2020 Q1
Quarterly report
7 May 20
10-K
2019 FY
Annual report
11 Mar 20
10-Q
2019 Q3
Quarterly report
7 Nov 19
10-Q
2019 Q2
Quarterly report
7 Aug 19
10-Q
2019 Q1
Quarterly report
9 May 19
10-K
2018 FY
Annual report
27 Feb 19
10-Q
2018 Q3
Quarterly report
6 Nov 18
10-Q
2018 Q2
Quarterly report
7 Aug 18
Current reports
8-K
Dynavax Announces Third Quarter 2020 Financial Results
5 Nov 20
8-K
Departure of Directors or Certain Officers
24 Sep 20
8-K
Other Events
14 Sep 20
8-K
Dynavax Announces Second Quarter 2020 Financial Results
6 Aug 20
8-K
Departure of Directors or Certain Officers
21 Jul 20
8-K
Preclinical results demonstrated the ability of CpG 1018-adjuvanted SCB-2019 to elicit neutralizing antibodies in multiple animal species
19 Jun 20
8-K
Departure of Directors or Certain Officers
29 May 20
8-K
Other Events
22 May 20
8-K
Other Events
21 May 20
8-K
Other Events
18 May 20
Registration and prospectus
S-3ASR
Automatic shelf registration
6 Aug 20
S-8
Registration of securities for employees
6 Aug 20
S-3ASR
Automatic shelf registration
2 Jul 20
424B5
Prospectus supplement for primary offering
22 May 20
424B5
Prospectus supplement for primary offering
21 May 20
POS AM
Prospectus update (post-effective amendment)
11 Mar 20
S-8
Registration of securities for employees
13 Aug 19
424B5
Prospectus supplement for primary offering
8 Aug 19
424B5
Prospectus supplement for primary offering
7 Aug 19
S-8
Registration of securities for employees
8 Jun 18
Proxies
DEFA14A
Additional proxy soliciting materials
22 May 20
DEFA14A
Additional proxy soliciting materials
17 Apr 20
DEF 14A
Definitive proxy
17 Apr 20
PRE 14A
Preliminary proxy
7 Apr 20
DEFA14A
Additional proxy soliciting materials
23 May 19
DEF 14A
Definitive proxy
22 Apr 19
DEF 14A
Definitive proxy
20 Apr 18
DEF 14A
Definitive proxy
10 Jul 17
PRE 14A
Preliminary proxy
30 Jun 17
DEF 14A
Definitive proxy
21 Apr 17
Other
CT ORDER
Confidential treatment order
30 Sep 20
EFFECT
Notice of effectiveness
1 May 20
CT ORDER
Confidential treatment order
7 Nov 19
CT ORDER
Confidential treatment order
17 Apr 19
CT ORDER
Confidential treatment order
16 Apr 18
CORRESP
Correspondence with SEC
7 Jul 17
UPLOAD
Letter from SEC
7 Jul 17
UPLOAD
Letter from SEC
6 Jul 17
EFFECT
Notice of effectiveness
26 Apr 17
CORRESP
Correspondence with SEC
24 Apr 17
Ownership
SC 13G/A
DYNAVAX TECHNOLOGIES / STATE STREET ownership change
13 Oct 20
4
DYNAVAX TECHNOLOGIES / Peter R. Paradiso ownership change
24 Sep 20
3
DYNAVAX TECHNOLOGIES / Peter R. Paradiso ownership change
24 Sep 20
4
DYNAVAX TECHNOLOGIES / Brent MacGregor ownership change
23 Jul 20
3
DYNAVAX TECHNOLOGIES / Brent MacGregor ownership change
23 Jul 20
4
DYNAVAX TECHNOLOGIES / JULIA MARIE EASTLAND ownership change
21 Jul 20
3
DYNAVAX TECHNOLOGIES / JULIA MARIE EASTLAND ownership change
21 Jul 20
4
DYNAVAX TECHNOLOGIES / Robert Janssen ownership change
20 Jul 20
4
DYNAVAX TECHNOLOGIES / Peggy V Phillips ownership change
29 May 20
4
DYNAVAX TECHNOLOGIES / NATALE S RICCIARDI ownership change
29 May 20
Patents
GRANT
Utility
Combination of a PD-1 antagonist and CPG-C type oligonucleotide for treating cancer
25 Aug 20
The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a Toll-like receptor 9 (TLR9) agonist that is a CpG-C type oligonucleotide, and the use of the combination therapies for the treatment of cancer.
GRANT
Utility
Cleavable conjugates of TLR7/8 agonist compounds, methods for preparation, and uses thereof
28 Jul 20
The present disclosure relates to cleavable conjugates (for example, particle-based or antibody-based conjugates) of TLR7/8 agonists (for example, 1H-imidazo[4,5-c]quinoline derivatives) containing a conjugation linker, a cleavable linker, and a self-eliminating linker.
APP
Utility
Alkyl Chain Modified Imidazoquinoline TLR7/8 Agonist Compounds and Uses Thereof
25 Jun 20
Disclosed are alkyl chain modified 1H-imidazoquinoline compounds, derivatives and analogs thereof, as Toll-like receptor-7 and -8 agonists for enhancing immune responses.
GRANT
Utility
Alkyl chain modified imidazoquinoline TLR7/8 agonist compounds and uses thereof
14 Apr 20
Disclosed are alkyl chain modified 1H-imidazoquinoline compounds, derivatives and analogs thereof, as Toll-like receptor-7 and -8 agonists for enhancing immune responses.
GRANT
Utility
Branched chimeric compounds, and methods of use thereof
4 Feb 20
The present disclosure relates to branched and linear chimeric compounds containing both nucleic acid and non-nucleic acid moieties, as well as to polynucleotides.